The Quantellect read.As of Nov 19, 2026, 8 active firms cover Aardvark Therapeutics, Inc. Common Stock: 3 rate it Buy or better, 4 sit at Neutral, and 1 rate it Sell or worse, a neutral consensus. The target range is very wide, $3.00 to $21.00 (about 7.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $8.00 sits 779% above the current $0.91. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.64 next quarter toward $-2.52 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Neutral
Strong Buy00%
Buy338%
Neutral450%
Sell113%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$8.00
+779.0% upside
Average target across 7 active firms as of Nov 19, 2026 vs $0.91 current
Highest Target$21.00
Average Target$8.00
Lowest Target$3.00
Detailed analyst forecasts for AARD
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 3 of 8 active firms rate AARD a Buy (4 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AARD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.64
Range $-0.87 – $-0.44 · 4 analysts · -35% YoY
Next period, 4 analysts expect Aardvark Therapeutics, Inc. Common Stock to earn $-0.64 a share (range $-0.87 – $-0.44), versus $-0.99 a year earlier. Full-year consensus is $-3.27, growing to $-2.52 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Aardvark Therapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AARD.
#1
Josh Schimmer
Cantor Fitzgerald · Rank #132
Buy
$50.00+5393.9% to target
Overall win rate
44%
+ Follow
#2
Leland Gershell
Oppenheimer · Rank #404
Buy
$21.00+2207.4% to target
Overall win rate
35%
+ Follow
#3
TA
Tazeen Ahmad
B of A Securities · Rank #411
Sell
$1.50+64.8% to target
Overall win rate
46%
+ Follow
#4
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Neutral
$4.00+339.5% to target
Overall win rate
36%
+ Follow
#5
Brian Abrahams
RBC Capital · Rank #502
Neutral
$2.50+174.7% to target
Overall win rate
26%
+ Follow
AARD stock forecast FAQ
What is AARD's average 12-month price target?+
The 7 active firms with a live target average $8.00 for Aardvark Therapeutics, Inc. Common Stock over the next 12 months, ranging from a $21.00 high to a $3.00 low, as of Nov 19, 2026.
Is AARD stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 8 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 4 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AARD?+
The Street-high target is $21.00 (Oppenheimer), and the Street-low is $3.00 (Morgan Stanley). The average of all 7 active-firm targets is $8.00.
How many active Wall Street firms cover AARD?+
8 active firms have a recognized rating on Aardvark Therapeutics, Inc. Common Stock as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AARD?+
Among analysts who currently cover AARD, Josh Schimmer of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #132). Their current call is Buy with a $50.00 target.
What is Aardvark Therapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.64 per share (range $-0.87 – $-0.44) across 4 analysts. Full-year EPS is projected at $-3.27, rising to $-2.52 the following year.
How much revenue is Aardvark Therapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading AARD lately?+
As of Nov 19, 2026, 3 of 8 active firms rate AARD a Buy (4 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AARD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.